Resverlogix Corp. (TSE:RVX – Get Free Report) hit a new 52-week low on Wednesday . The stock traded as low as C$0.04 and last traded at C$0.06, with a volume of 177015 shares traded. The stock had previously closed at C$0.06.
Resverlogix Stock Performance
The firm has a market cap of C$15.12 million, a price-to-earnings ratio of -0.69 and a beta of 0.69. The firm has a 50-day moving average price of C$0.06 and a two-hundred day moving average price of C$0.06.
Resverlogix (TSE:RVX – Get Free Report) last released its quarterly earnings results on Monday, April 1st. The biotechnology company reported C($0.01) earnings per share (EPS) for the quarter. Research analysts anticipate that Resverlogix Corp. will post -0.22 earnings per share for the current year.
About Resverlogix
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
See Also
- Five stocks we like better than Resverlogix
- How to Invest in the Best Canadian Stocks
- AbbVie Stock: A Perfect Dip for Investors to Buy
- 5 discounted opportunities for dividend growth investors
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- What is the Australian Securities Exchange (ASX)
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
